Imaging techniques in Alzheimer's disease: a review of applications in early diagnosis and longitudinal monitoring
WM van Oostveen, ECM de Lange - International journal of molecular …, 2021 - mdpi.com
Background. Alzheimer's disease (AD) is a progressive neurodegenerative disorder
affecting many individuals worldwide with no effective treatment to date. AD is characterized …
affecting many individuals worldwide with no effective treatment to date. AD is characterized …
Multimodal imaging in Alzheimer's disease: validity and usefulness for early detection
Alzheimer's disease is a progressive neurodegenerative disease that typically manifests
clinically as an isolated amnestic deficit that progresses to a characteristic dementia …
clinically as an isolated amnestic deficit that progresses to a characteristic dementia …
Mild cognitive impairment
RC Petersen - New England Journal of Medicine, 2011 - Mass Medical Soc
Mild Cognitive Impairment | New England Journal of Medicine Skip to main content The New
England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES Cardiology …
England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES Cardiology …
Comparing predictors of conversion and decline in mild cognitive impairment
Objective: A variety of measurements have been individually linked to decline in mild
cognitive impairment (MCI), but the identification of optimal markers for predicting disease …
cognitive impairment (MCI), but the identification of optimal markers for predicting disease …
Mild cognitive impairment: an overview
RC Petersen, S Negash - CNS spectrums, 2008 - cambridge.org
Mild cognitive impairment (MCI) refers to the transitional state between the cognitive
changes of normal aging and very early dementia. MCI has generated a great deal of …
changes of normal aging and very early dementia. MCI has generated a great deal of …
[HTML][HTML] Biomarkers for the early detection and progression of Alzheimer's disease
The recent failures of potential disease-modifying drugs for Alzheimer's disease (AD) may
reflect the fact that the enrolled participants in clinical trials are already too advanced to …
reflect the fact that the enrolled participants in clinical trials are already too advanced to …
Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias
This multicenter study examined 18F-FDG PET measures in the differential diagnosis of
Alzheimer's disease (AD), frontotemporal dementia (FTD), and dementia with Lewy bodies …
Alzheimer's disease (AD), frontotemporal dementia (FTD), and dementia with Lewy bodies …
Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease
One of the main features of Alzheimer's disease (AD) is the severe reduction of the cerebral
metabolic rate for glucose (CMRglc). In vivo imaging using positron emission tomography …
metabolic rate for glucose (CMRglc). In vivo imaging using positron emission tomography …
Glucose metabolism in normal aging and Alzheimer's disease: methodological and physiological considerations for PET studies
L Mosconi - Clinical and translational imaging, 2013 - Springer
Alzheimer's disease (AD) is an age-dependent neurodegenerative disorder associated with
progressive loss of cognitive function. 2-[18 F] fluoro-2-deoxy-d-glucose (FDG) positron …
progressive loss of cognitive function. 2-[18 F] fluoro-2-deoxy-d-glucose (FDG) positron …
Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia
Alzheimer's disease (AD) is a progressive age-related neurodegenerative disease. At the
time of clinical manifestation of dementia, significant irreversible brain damage is already …
time of clinical manifestation of dementia, significant irreversible brain damage is already …